08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Benten BioServices Inc., Deltagen deal

Drug discovery company Deltagen acquired contract service company Benten in a stock deal valued at $1.1 million based on Deltagen's close of $0.12 on Dec. 9, the last trading day before the deal was announced....
01:21 , Mar 16, 2007 |  BC Extra  |  Company News

Roche returns rights to Trimeris' fusion inhibitor IP

TRMS announced late Thursday that partner Roche (SWX:ROG) returned all rights to joint patents and other IP under the companies' 2000 research deal for TRMS's next-generation fusion inhibitor peptides to treat HIV. TRMS will pay...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

Deltagen board of directors update

Deltagen Inc. (DGEN), San Carlos, Calif.   Business: Genomics, Functional genomics   Appointed: Robert Driscoll, president, CEO and secretary; Philippe Chambon, a managing director at New Leaf Venture Partners; and Martin Hernon, a general partner...
07:00 , Apr 3, 2006 |  BC Week In Review  |  Company News

Deltagen management update

Deltagen Inc. (DGEN), San Carlos, Calif.   Business: Genomics, Functional genomics   Promoted: Winston Thomas to COO from VP of operations; Shera Kash to VP from director of operations; and Robert Driscoll to president, CEO...
08:00 , Jan 16, 2006 |  BC Week In Review  |  Company News

Charles River Laboratories Inc., Deltagen deal

CRL received exclusive worldwide rights to supply Deltagen's repository materials for knockout mice. The repository includes cryopreserved mouse embryos, sperm and ES cells. Charles River Laboratories Inc. (CRL), Wilmington, Mass.   Deltagen Inc. , San...
07:00 , Oct 10, 2005 |  BC Week In Review  |  Company News

Deltagen, Lexicon Genetics Inc., National Institutes of Health genomics news

The NIH granted each company a three-year contract to provide knockout mouse lines and related phenotypic data. The contracts are part of the institute's Knockout Mouse Project, in which NIH is compiling a resource of...
07:00 , Sep 12, 2005 |  BC Week In Review  |  Company News

Deltagen, Stem Cell Sciences deal

Deltagen received a license to use STEM's IRES (internal ribosome entry site) gene expression technology to manufacture, sell and sublicense knockout mice. Also, Deltagen will provide STEM with genetically engineered mice. STEM will receive $1.2...
07:00 , Apr 4, 2005 |  BC Week In Review  |  Company News

Lexicon Genetics Inc., Deltagen functional genomics news

The court overseeing Deltagen's bankruptcy proceedings awarded LEXG an initial payment of $4 million as part of a settled a breach of contract claim related to gene-targeting technologies for the generation of knockout mice. LEXG...
07:00 , Sep 6, 2004 |  BioCentury  |  Strategy

Asset accumulation

A few months ago, BioCentury spilled a lot of ink to deconstruct the NRDO model of no-research, development only companies being formed to scavenge for products or technologies that can be commercialized quickly and offer...
08:00 , Jan 12, 2004 |  BC Week In Review  |  Company News

Prometheus management update

Prometheus Laboratories Inc. , San Diego, Calif.   Business: Gastrointestinal, Autoimmune, Inflammation   Hired: Joseph Limber as president, CEO and a director, formerly interim CEO of Deltagen Inc.  ...